benefit from structurally improving margins and capturing the volume opportunities. IVL has achieved notable progress on multiple strategic fronts and is increasingly well positioned to deliver sustainable
- commissioning activities planned in December 2017 and startup early 2018. In addition to improved cash flows as a result of the better performance, the Company’s Balance Sheet al- so strengthened as a consequence
well on track. After having over- delivered on our targets by 21% in 2020, IVL has made progress as planned in 1Q21. The program has yielded US$67M this quarter, split evenly between business-led
qualified opinion as well as appointment of independent directors who have already been appointed for more than 3 terms or 9 years. Besides, progress on anti-corruption policy will also be monitored for the
profit for 1.98 million baht or 41.68%. It is because the Company is more well-known and the customer base is extensively extended. 3 The combination of those two incomes results in the Company Group’s
diseases, emergency care etc. In addition, an emphasis on health service for well people such as physical checkup center by launching the new campaigns targeting market in Trang and nearby provinces in order
. PET production at Poland and Alphapet USA were also impacted due to temporary shutdowns as well as an extended shutdown of the EO-EG facility. All these facilities are now back on stream. Core
, diversified and steady cash flows making it a unique world-class chemical company. This acquisition will be funded by cash and debt and there is no equity dilution anticipated. IVL balance sheet was
Industry fundamentals continue to be positive, led by strong demand growth outlook for 100% recyclable PET, supply balance and on-going restructuring seen in the PET and PTA industry with limited new supply